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Abstract
Meniere’s disease is an inner ear disorder that can manifest as fluctuating vertigo, sensorineural hearing loss, tinnitus, and
aural fullness. However, the pathologic mechanism of Meniere’s disease is still unclear. In this study, we evaluated
autoimmunity as a potential cause of Meniere’s disease. In addition we tried to find useful biomarker candidates for
diagnosis. We investigated the protein composition of human inner ear fluid using liquid column mass spectrometry, the
autoimmune reaction between circulating autoantibodies in patient serum and multiple antigens using the Protoarray
system, the immune reaction between patient serum and mouse inner ear tissues using western blot analysis. Nine proteins,
including immunoglobulin and its variants and interferon regulatory factor 7, were found only in the inner ear fluid of
patients with Meniere’s disease. Enhanced immune reactions with 18 candidate antigens were detected in patients with
Meniere’s disease in Protoarray analysis; levels of 8 of these antigens were more than 10-fold higher in patients than in
controls. Antigen-antibody reactions between mouse inner ear proteins with molecular weights of 23–48 kDa and 63–
75 kDa and patient sera were detected in 8 patients. These findings suggest that autoimmunity could be one of the
pathologic mechanisms behind Meniere’s disease. Multiple autoantibodies and antigens may be involved in the
autoimmune reaction. Specific antigens that caused immune reactions with patient’s serum in Protoarray analysis can be
candidates for the diagnostic biomarkers of Meniere’s disease.
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Introduction
In 1861, Prosper Meniere first described Meniere’s disease as an
inner ear disorder that manifests as fluctuating vertigo, sensori-
neural hearing loss, tinnitus, and aural fullness. The prevalence of
Meniere’s disease is 3.5–513 per 100,000, which is higher than the
prevalence of systemic lupus erythematosus (SLE) and multiple
sclerosis [1]. The unpredictable nature of Meniere’s disease has a
serious effect on patients’ daily life. During active episodes, the
quality of life score of patients with Meniere’s disease is thought to
be lower than that of AIDS patients treated with AZT, that of
patients with severe chronic obstructive pulmonary disease, and
that of non-institutionalized patients with Alzheimer’s disease [2].
The main pathologic site is thought to be the inner ear, which
consists of the cochlea, vestibule, and endolymphatic sac. A
characteristic finding of Meniere’s disease is the dilatation of the
endolymphatic compartment of the inner ear caused by an
increase in endolymph (endolymphatic hydrops, Fig. 1) [3]. The
proposed etiologies of endolymphatic hydrops are autoimmune,
allergic, genetic, traumatic, and infectious (viral) [4–9]. These
finally result in endolymphatic hydrops by deteriorating ion
homeostasis and fluid volume regulation in the inner ear [3].
However, the exact pathologic mechanism underlying endolym-
phatic hydrops is still unknown.
Certain findings have provided evidence that autoimmunity
may underlie the pathology of Meniere’s disease. The prevalence
of systemic autoimmune diseases such as rheumatoid arthritis,
ankylosing spondylitis, and SLE in patients with Meniere’s disease
is 3- to 8-fold higher than in the general population [10]. In
addition, autoantibodies such as the anti-heat-shock protein 70,
anti-68 kD inner ear protein antibody, anti-myelin peroxidase
zero antibody, and anti-thyroid peroxidase antibody have been
detected in the serum of patients with Meniere’s disease [11–14].
However, these autoantibodies were not found in all of the
patients.
Previous studies tended to investigate only a select few target
proteins instead of conducting mass screening; in addition, many
of these studies used western blot analyses to detect antigen-
antibody reactions between patient serum and animal inner ear
tissues, which can demonstrate the existence of an antigen-
antibody reaction but provides no information on the identity of
the autoantibody. Few studies demonstrated increased proteins in
the serum of Meniere’s disease patients that were reported to be
related with inflammatory reaction or inner ear disorders by
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proteomics technique [15]. But, there was no evidence if these
materials existed in the inner ear fluid of Meniere’s disease
patients. Studies using human inner ear tissue are rare, and no
studies have investigated autoimmunity using human inner ear
fluid. To overcome the limitations of previous studies and to
understand the autoimmune pathologic mechanisms underlying
Meniere’s disease, mass screening-based studies of autoimmune
reactions using human inner ear fluid and sera of patients should
be conducted.
In this study, we tried to provide evidence for the involvement of
autoimmunity in Meniere’s disease and identify the candidate
antigens that react with autoantibodies, which can suggest
diagnostic biomarker candidates for Meniere’s disease. Several
studies were performed. First, the protein composition of inner ear
fluid from control patients and patients with Meniere’s disease was
compared using proteomic analysis. Second, candidate autoanti-
gens that reacted with circulating autoantibodies in patient serum
were investigated using protein array (Protoarray, Invitrogen, Life
Technologies, Grand Island, NY). Third, western blots using
patient serum and mouse inner ear tissues were performed to
investigate whether the circulating autoantibodies reacted with
inner ear tissue. The results of this study can provide the basic
information for the development of diagnostic biomarkers as well
as the understanding of pathologic mechanisms of Meniere’s
disease.
Methods
Selection of patients and controls
Thirteen patients diagnosed with Meniere’s disease according to
the criteria of the American Academy of Otolaryngology Head
and Neck Surgery (1995) [16] were enrolled in the patient group.
Samples of inner ear fluid (endolymphatic sac luminal fluid) were
taken from 3 patients undergoing endolymphatic sac surgery to
treat their intractable disease, and peripheral blood was sampled
from the other 10 patients. Three patients with acoustic tumors
and 10 patients with simple tympanic membrane perforation who
planned to undergo myringoplasty were enrolled as controls.
Endolymphatic sac luminal fluid was sampled from the 3 controls
during the acoustic tumor surgery via the translabyrinthine
approach, and peripheral blood was sampled in the other 10
controls. The controls with acoustic tumors had severe sensori-
neural hearing loss but no history of sudden vertigo. The controls
had no history of sensorineural hearing loss or vertigo, and their
audiograms showed mild conductive hearing loss. None of the
patients or controls had a history of systemic disease, and all of
their laboratory parameters, including the electrocardiogram,
chest radiography, blood cell counts (red blood cells, white blood
cells, and platelets), liver and kidney function tests, and urinalysis,
were normal. The gender distribution and mean age of the
patients and controls were not significantly different (p.0.05 for
the chi-square test and t-test, Table 1).
Sampling of inner ear fluid and sera
Three patients with Meniere’s disease underwent endolymphat-
ic sac surgery for their intractable disease and the 3 controls with
acoustic tumors underwent tumor removal via the translabyr-
inthine approach. To obtain inner ear fluid, endolymphatic sac
luminal fluid was sampled during surgery. In each surgical
procedure, the endolymphatic sac should be fully exposed.
Because the amount of luminal fluid was very small (,4 ml), we
infused 200 ml of normal saline into the endolymphatic sac and
aspirated the diluted luminal fluid from the endolymphatic sac, as
previously described [17]. The fluid samples were immediately
stored at 280uC until analysis.
Blood was sampled from the other 10 participants in each group
for serum protein analysis. The blood was stored in a tube
containing ethylenediaminetetraacetic acid. The plasma was
immediately separated and stored at 280uC until analysis.
One-dimensional electrophoresis (1-DE) of
endolymphatic sac luminal fluid
1-DE was performed to compare the protein composition of the
fluid of patients with Meniere’s disease and that of controls. Thirty
micrograms of protein from the diluted luminal fluid was used for
1-DE for each sample. The samples were lyophilized and dissolved
in 15 ml of distilled water. Samples were subjected to sodium
dodecyl sulfate gel electrophoresis on an 8–16% Tris/Glycine gel
and stained with Coomassie Brilliant Blue.
Identification of endolymphatic sac luminal fluid proteins
by liquid column mass spectrometry (LC-MS/MS)
The entire 1-DE gel lane was cut into 8 pieces according to
molecular weight for digestion. After reduction with dithiothretol
and alkylation with iodoacetamide, each piece of gel was treated
with trypsin for in situ digestion. It was then washed with 10 mM
ammonium bicarbonate and 50% acetonitrile, swollen in digestion
buffer containing 50 mM ammonium bicarbonate, 5 mM CaCl2,
and 1 mg of trypsin. Next, it was incubated at 37uC for 12 h.
Peptides were recovered over the course of 2 extraction cycles with
50 mM ammonium bicarbonate and 100% acetonitrile. The
resulting peptide extracts were pooled, lyophilized, and stored at
220uC.
Nano LC-MS/MS analysis was performed on an Agilent 1100
Series nano-LC and linear trap quadrupole (LTQ)-mass spec-
trometer (Thermo Electron, San Jose, CA). The capillary column
used for LC-MS/MS analysis (150 mm60.075 mm) was obtained
from Proxecon (Odense M, Denmark) and slurry-packed in-house
with 5 mg, 100 A˚ pore size Magic C18 stationary phase (Michrom
Bioresources, Auburn, CA). The mobile phase A for LC
separation was 0.1% formic acid in deionized water and the
mobile phase B was 0.1% formic acid in acetonitrile. Chroma-
tography was performed using a linear gradient from 5% B to 35%
B over 100 min, from 40% B to 60% B over 10 min, and from
60% B to 80% B over 20 min. The flow rate was maintained at
300 nl/min after splitting. Mass spectra were acquired using data-
dependent acquisition with full mass scan (400–1800 m/z)
followed by MS/MS scans. Each acquired MS/MS scan
represented the average of one microscan on the LTQ. The
Figure 1. Schematic drawing of the inner ear and endolym-
phatic hydrops as a mechanism for Meniere’s disease. The inner
ear consists of the cochlea, vestibule, and endolymphatic sac (ES). The
utricle (U), saccule (S), and semicircular canals (SCCs) form the vestibule.
A. Normal inner ear structure. B. Endolymphatic hydrops in patients
with Meniere’s disease.
doi:10.1371/journal.pone.0111039.g001
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temperature of the ion transfer tube was controlled at 200uC and
the spray was 1.5–2.0 kV. The normalized collision energy was set
at 35% for MS/MS.
The MASCOT and SEQUEST (BioWorks software version
3.2, Thermo Electron) search engines were used to search the
UniProt human protein databases (release 14.8; 82728 sequences)
for the tandem mass spectra. Mass tolerances of 1.2 Da and
0.6 Da were used for precursor and fragment ions, respectively.
The search included variable modification of oxidation on
methionine and carbamidomethyl of cysteine. PeptideProphet
and ProteinProphet were used to estimate the false discovery rate
(FDR) for any minimum probability used as a cut-off for
MASCOT and SEQUEST search results.
Protoarray analysis of serum samples (Immune Response
Biomarker Profiling)
To investigate the presence of autoantibodies and their target
antigens, Protoarray (Human Protein Microarray v5.0 containing
9400 human proteins, Invitrogen) analysis was performed with
sera from patients and controls according to the manufacturer’s
protocol. Briefly, after blocking array slides with blocking buffer
for 1 h, we washed the slides with washing buffer for 5 min, and
5 ml of diluted serum (1:500) was placed on the slides. The slides
were incubated for 90 min and washed 4 times for 5 min with
washing buffer. After washing, Alexa Fluor 647 (final concentra-
tion of 1 mg/ml) was added on the slide, and the slides were
incubated for 90 min. The antibody was aspirated, and the slides
were washed for 5 min 4 times. These steps were performed at
4uC. The slides were dried immediately by centrifugation at
2006g for 1 min and stored in a slide box to protect them from
light until scanning was performed. The dried arrays were scanned
using a GenePix 4000B microarray scanner (Molecular Devices,
Sunnyvale, CA). Genepix Pro microarray data acquisition
software was used to align the scanned image with the template
and to acquire the pixel intensity data for each spot on the array.
The reported pixel intensity was calculated as the average of
duplicate signals obtained after subtracting the background signal.
Protoarray Prospector software (Life Technologies) was used to
analyze the data, perform background subtraction, and normalize
the signals. The normalized signal intensities obtained for controls
and patients were compared with a t-test, and differences were
considered significant at p,0.05.
Western blotting
To investigate whether antibodies in the patient serum reacted
with inner ear tissue, western blots using patient serum and mouse
inner ear tissue were performed. We used mouse inner ear tissue
for ethical reasons and because it would have been technically
difficult to harvest the entire human cochlea and vestibule. Eight-
week-old male C57BL/6 mice were used. The entire inner ear was
separated from the temporal bone of the mouse. The cochlea and
vestibule were separated, and the membranous labyrinth of the
cochlea and vestibule were carefully dissected. Each membranous
labyrinth was lysed with 26 sample buffer (250 mM Tris-HCl
[pH 6.5], 2% sodium dodecyl sulfate (SDS), 1% DTT, 0.02%
bromophenol blue, and 10% glycerol). Protein levels were
quantified by comparing the absorbance of the lysate with that
of serially diluted bovine serum albumin (0, 0.2, 0.4, 0.6, 0.8, and
1 mg/ml) in the VersaMax ELISA plate reader (Molecular
Devices). Samples were heated for 5 min at 95uC. Equal total
amounts of protein were prepared for each gel lane. A colored
marker mixture was used to estimate the molecular weights of the
bands. Proteins were separated using 10% SDS-polyacrylamide
gel at 125 V for 4 h with a running buffer (25 mM Tris-Base,
192 mM glycine and 0.1% SDS) and transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, MA) using a semi-dry
transfer cell (Bio-Rad, Hercules, CA) for 2 h at 200 mA and a
transfer buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05%
Tween 20). The membranes were blocked with 5% skim milk in
Tris-buffered saline (TBS; 50 mM Tris-HCl [pH 7.5] and
150 mM NaCl) for 2 h at room temperature. The blot was
incubated overnight with patient serum diluted at 1:200 in 0.5%
Tween-20 in TBS. The blot was washed with TTBS, incubated
with a secondary anti-human antibody (Cell Signaling Technol-
ogy, Danvers, MA) in TTBS for 45 min at room temperature, and
visualized by enhanced chemiluminescence (Amersham Biosci-
ences, Champaign, IL).
Ethics statement
This study was approved by the institutional review board of
Severance Hospital (approval number 4-2011-0871 and 4-2013-
0483), and written informed consent was obtained from all of the
participants. Institutional Animal Care and Use Committee of
Yonsei University College of Medicine approved this study and all
mice were treated in accordance with the guidelines for the Care
and Use of Laboratory Animals of Yonsei University College of
Medicine (approval number 2011-0084).
Results
Difference in the protein composition of the ES luminal
fluid of controls and patients
The density and distribution of protein bands in the 1-DE of ES
luminal fluid from controls and patients with Meniere’s disease
varied (Fig. 2); the density and molecular weight of bands from the
patients and controls were identical in some cases and different in
others. For example, the bands located between 63 and 75 kDa





Male to female ratio
Controls 1:2 7:3
Patients 1:2 5:5
Mean age in years (mean 6 SD)
Controls 47.3 6 5.5 43.1 6 7.8
Patients 39.0 6 22.5 49.6 6 7.0
doi:10.1371/journal.pone.0111039.t001
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associated with control 1 and 2 (C1 and C2) and patient 1 (P1)
appeared similar, but the bands associated with control 3 (C3) and
patient 2 and 3 (P2 and P3) appeared denser. The bands located
between 17 and 35 kDa and between 75 and 180 kDa also varied.
Consequently, the distribution and density of protein bands
differed for each individual, and it was difficult to identify disease-
specific protein bands.
To identify differences in the protein composition of the ES
luminal fluid of controls and patients with Meniere’s disease and to
identify disease-specific proteins, LC-MS/MS was performed with
proteins extracted from 1-DE gels from each control and patient.
A total of 6784 (C1, FDR of 1.86%), 6108 (C2, FDR of 0.95%),
3114 (C3, FDR of 1.68%), 6961 (P1, FDR of 1.35%), 7740 (P2,
FDR of 3.11%), and 763 (P3, FDR of 2.00%) proteins were
detected in the LC-MS/MS analysis. Immunoglobulin and its
variants were the most commonly identified proteins (49% and
58% of all proteins in the luminal fluid of controls and patients,
respectively).
We analyzed the proteins that were found only in the luminal
fluid of patients with Meniere’s disease. First, common proteins
found in the luminal fluid of all of the patients with Meniere’s
disease were analyzed. A total of 180 proteins were identified in
this analysis, 76% of which were immunoglobulin and its variants;
albumin, keratin, globin, transferrin, protease inhibitor, and
complement were also detected (Fig. 3). Then, proteins that were
also detected in controls were excluded from the 180 proteins. As a
result, nine proteins were identified: 8 consisted of immunoglob-
ulin and its variants, and 1 was interferon regulatory factor 7
(Table 2 and Table S1). With the exception of the immunoglob-
ulin kappa light chain variable region (gi|4323924), which had a
molecular weight of 17–26 kDa, all of the proteins had a
molecular weight of 55–63 kDa. Consequently, the proteins
detected only in the luminal fluid of Meniere’s disease patients
were those involved in the inflammatory or immune reactions.
Reaction of antigens with patient sera in the Protoarray
analysis
We investigated the presence of circulating autoantibodies in
the peripheral blood of the 10 patients with Meniere’s disease
using Protoarray Immune Response Biomarker Profiling. Eighteen
proteins had more than 2-fold greater signal intensity in the
patients with Meniere’s disease than in the controls (p,0.05); the
signal intensity of 8 proteins was more than 10-fold higher in the
patients than in the controls (Table 3, Fig. 4). Among them, the
signal intensity of the immunoglobulin heavy constant gamma 1
(IGHG1) was approximately 205-fold higher in the patients than
in the controls. A number of antigens had a sensitivity and
specificity of .60% and .80%, respectively: IGHG1, the
regulator of G-protein signaling 10 (RGS10), transcript variant
2, chromosome 2 open reading frame 34 (C2orf34), and SH3-
domain GRB2-like endophilin B1 (SH3GLB1) had a sensitivity
and specificity of 80%; the cDNA clone IMAGE:4155919,
complete cds, calcium/calmodulin-dependent protein kinase IV
(CAMK4), GSG1-like (GSG1L), transcript variant 2, mRNA, and
NIMA (never in mitosis gene a)-related kinase 7 (NEK7) had a
sensitivity of 70% and a specificity of 80%; and neural cell
adhesion molecule 2 (NCAM2) had a sensitivity of 60% and a
specificity of 90%. The 8 proteins with more than 10-fold higher
signal intensity in the patients had a sensitivity and specificity of .
70% and 80%, respectively, for Meniere’s disease except
Aminoacylase 1 (ACY1) which had a sensitivity and specificity of
100% and 50%, respectively (Fig. 4). More information on
antigens with signal intensity more than 2-fold higher in the
patients is provided in Table S2. These results provide evidence
for the existence of circulating autoantibody and enhanced
autoimmune/immune reactions in patients with Meniere’s disease.
Reaction of inner ear tissue antigens with patient sera
Western blotting (Fig. 5) was performed to investigate whether
the sera from patients with Meniere’s disease could produce an
antigen-antibody reaction with inner ear tissue. There were no
single disease-specific bands for an antigen-antibody reaction in
the patients; instead bands corresponding to a molecular weight of
63–75 kDa and 25–48 kDa were more frequently found in the
patients with Meniere’s disease (Fig. 5).
Bands corresponding to a molecular weight of 63–75 kDa were
detected in 6 of the patients and in 2 of the controls (red arrows in
Fig. 5). Evidence of an antigen-antibody reaction both in the
cochlear and vestibular tissues was detected in 3 of the 6 samples
from patients with Meniere’s disease; evidence of an antigen-
antibody reaction only in the vestibular tissues was observed in 2 of
the 6 samples, whereas evidence for this reaction only in the
cochlear tissues was observed in 1 of the 6 samples. Evidence for
an antigen-antibody reaction both in the cochlear and vestibular
tissues was observed only in one of the controls (C7) and a weak
reaction was observed only in the cochlear tissue in another one of
the controls (C9) (Fig. 5).
Bands distributed between 25–48 kDa were detected in 7 of the
patients with Meniere’s disease and in 2 of the controls (blue and
yellow arrows in Fig. 5). The reaction was detected only in the
vestibular tissues in 5 of the 7 patient samples and both in the
cochlear and vestibular tissues in 2 of the patient samples. The
reaction was detected only in the cochlea in 1 of the controls and
both in the cochlea and vestibule in the other control.
We evaluated whether the antigens that reacted with patient
serum in the Protoarray experiment had molecular weights of 25–
48 kDa and 63–75 kDa, as shown in our western blot data. The
following proteins had molecular weights in the ranges of interest:
C12orf48 (65.1 kDa), PCLO (46 kDa), ACY1 (45.9 kDa), NPY2R
(42.7 kDa), B3GALT4 (41.5 kDa), SH3GLB1 (40.8 kDa),
HNRPH3, transcript variant 2H9A (36.9 kDa), GSG1L, tran-
script variant 2, mRNA (36.8 kDa), C2orf34 (36.1 kDa), IGHG1
(36.1 kDa), and NEK7 (34.6 kDa). These antigens could be
involved in inner ear autoimmune reactions. Among the proteins,
C12orf48 was the only protein which produced a significantly
Figure 2. 1-DE of the proteins in the endolymphatic sac luminal
fluid of each control and patient. The distribution of bands in each
individual varied. C, control; P, patient.
doi:10.1371/journal.pone.0111039.g002
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lower signal intensity in the patients without an antigen-antibody
reaction in western blots (P1, P2 in Fig. 5) than in the patients with
a detectable antigen-antibody reaction in western blots (P3–P10).
However, without peptide sequencing, we cannot determine
whether the protein was a specific antigen involved in an immune
reaction.
Our results imply that multiple autoantibodies or antigens
rather than a specific antibody or antigen can cause autoimmune
reactions in the inner ear that result in Meniere’s disease.
Discussion
The pathophysiology of Meniere’s disease is still unknown, and
various etiologies have been proposed. One of the proposed
etiologies of Meniere’s disease is autoimmunity; this putative
etiology is supported by the fact that this disease often occurs
bilaterally (in 25–40% of patients), responds to glucocorticoids and
anti-inflammatory treatments, and is characterized by elevated
levels of autoantibodies or circulating immune complexes and
antigen-antibody reactions between patient serum and animal
inner ear tissues [18]. However, Meniere’s disease does not always
occur bilaterally, and experimental studies have only been
performed on small numbers of patients or have only targeted a
restricted number of autoantibodies or inflammatory markers.
Although the number of patients enrolled in this study was
small, we found reliable evidence for the inner ear immune/
inflammatory reaction in patients with Meniere’s disease by
investigating the protein composition of the inner ear fluid in
diseased patients and controls. We also mass screened for
autoantibody-antigen reactions using the Protoarray system and
detected antigen-antibody reactions using patient serum and
mouse inner ear tissues. Most of these methods have not been used
in previous experiments. The results of this study will contribute to
the development of more cost-effective and efficient methods for
screening and detecting autoimmune reactions in large numbers of
patients with Meniere’s disease.
Analysis of ES luminal fluid and evidences of immune
reaction
Autoimmune reactions in the inner ear may cause damage to
the epithelial layers surrounding the endolymphatic space. In such
an instance, fluid in the endolymphatic space should contain
evidence of immunologic reactions, including autoantibodies such
as those found in the synovial fluid of patients with rheumatoid
Figure 3. Distribution of common protein components of the endolymphatic sac luminal fluid of Meniere’s disease patients. P,
patient.
doi:10.1371/journal.pone.0111039.g003






gi|34536154 Unnamed protein product 26.3 387
gi|56786126 AF1 non-allergic IgE heavy chain IGHV3-74 27.4 133
gi|1871491 IgM 41.4 180
gi|886286 This CDS feature is included to show the translation of the corresponding V_region.
Present translation qualifiers on V_region features are illegal
32.6 102
gi|21668608 Immunoglobulin heavy chain VHDJ region 34.2 69
gi|33319532 Ig heavy chain variable region; VH3 family 52.5 117
gi|33319348 Ig heavy chain variable region; VH3 family 21.7 112
gi|4323924 Immunoglobulin kappa light chain variable region 29 44
gi|1621457 Interferon regulatory factor 7 9.3 64
Protein searches were conducted in MASCOT (version 2.2.04) using the NCBI database. The search parameters were as follows: 1) Enzyme specificity – Trypsin; 2) Maxi-
mum missed cleavages –1; 3) Carbamidomethyl (C); Oxidation (M) as variable modifications; MASCOT results were filtered using a protein probability value of less than
0.05. Individual peptide sequences and scores were provided as Table S1.
doi:10.1371/journal.pone.0111039.t002
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arthritis. Thus, analyses of the endolymph can provide evidence
for the involvement of autoimmunity in the pathogenesis of
Meniere’s disease.
We analyzed the protein composition of the inner ear fluid of
diseased and control groups to find evidence suggesting that
increased immune or inflammatory reaction is involved in the
pathogenesis of Meniere’s disease. Proteomic techniques (LC-MS/
MS) were used to analyze the protein constituents of the inner ear
fluid. We used ES luminal fluid because the protein concentrations
in this fluid are very high [17] and because the ES is the site where
most immunologic reactions occur in the inner ear [19–21]. In
addition, sampling the ES luminal fluid does not usually affect
inner ear function; indeed, the 3 patients enrolled in this
experiment who underwent ES surgery had preserved inner ear
functions after sampling.
The use of cochlear and vestibular endolymph in addition to ES
luminal fluid would have improved our study; however, sampling
the cochlear and vestibular endolymph in patients with Meniere’s
disease would have been impossible because the inner ear function
of the patients would have been destroyed and the protein
concentrations in these compartments would have been too low
for the analysis.
The most commonly encountered proteins in the ES luminal
fluid were immunoglobulins and their variants. This is expected, as
the ES is a known site of immunologic responses in the inner ear.
However, the only proteins that were detected exclusively in the
Table 3. Proteins with higher signal intensities in Meniere’s disease in the Protoarray analysis.
Accession No. Swissprot ID Protein name
Fold
change Function
BC014667.1 P01857 Immunoglobulin heavy constant
gamma 1 (G1m marker) (IGHG1)
204.9 Humoral immunity.
NM_002925.3 O43665 Regulator of G-protein signaling
10 (RGS10), transcript variant 2
27.6 Inhibits signal transduction by increasing the GTPase
activity of G protein alpha subunits.
BC053733.1 Q7Z624 Chromosome 2 open reading
frame 34 (C2orf34)
25.7 Catalyzes the trimethylation of ‘Lys-116’ in calmodulin.
NM_016009.2 Q9Y371 SH3-domain GRB2-like
endophilin B1 (SH3GLB1)
20.7 May be required for normal outer mitochondrial
membrane dynamics.
NM_000666.1 Q03154 Aminoacylase 1 (ACY1) 16.4 Involved in the hydrolysis of N-acylated or N-acetylated
amino acids (except L-aspartate).




protein kinase IV (CAMK4)
14.0 Calcium/calmodulin-dependent protein kinase that
operates in the calcium-triggered CaMKK-CaMK4
signaling cascade.
NM_144675.1 Q8TB81 GSG1-like (GSG1L), transcript variant 2,
mRNA.
10.3 Modifies AMPA receptor (AMPAR) gating.
NM_133494.1 Q8TDX7 NIMA (never in mitosis gene a)- related
kinase 7 (NEK7)
9.7 A protein kinase that plays an important role in mitotic
cell cycle progression.
NM_003782.3 O96024 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase,
polypeptide 4 (B3GALT4)
8.1 Involved in GM1/GD1B/GA1 ganglioside biosynthesis.
NM_001011700.1 P59942 Mitochondrial coiled-coil domain
protein 1 (MCCD1)
7.5 Unknown.
BC052946.1 O15394 Neural Cell Adhesion Molecule 2
(NCAM2)
6.1 May play important roles in selective fasciculation and
zone-to-zone projection of the primary olfactory axons.
NM_000910.1 P49146 Neuropeptide Y Receptor Y2 (NPY2R) 5.9 Receptor for neuropeptide Y and peptide YY.




3.1 Involved in splicing and participates in early heat shock-
induced splicing arrest.
BC050696.1 Q9NWS1 Chromosome 12 Open Reading
Frame 48 (C12orf48)
2.8 Plays a central role in DNA repair and in the maintenance
of genomic stability by suppressing inappropriate
homologous recombination.
BC093864.1 Q92796 Disks large homolog 3 (DLG3) 2.4 Required for learning, most likely due to its role in
promoting synaptic plasticity following NMDA receptor
signaling.
NM_001157.2 P50995 Annexin A11 (ANXA11),
transcript variant
2.0 Required for mid-body formation and completion of the
terminal phase of cytokinesis.
BC001304.1 Q32P40 Piccolo (presynaptic cytomatrix
protein) (PCLO)
2.0 May be involved in maintaining the neurotransmitter
release site in register with postsynaptic reception
apparatus.
Protein information was obtained from http://www.uniprot.org/.
Proteins for which the Protoarray signal intensity was more than 2-fold higher in the patients with Meniere’s disease than in the controls were listed (p,0.05).
doi:10.1371/journal.pone.0111039.t003
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patients with Meniere’s disease were immunoglobulins, their
variants, and interferon gamma regulatory factor, suggesting that
increased inflammatory reactions in the inner ear may contribute
to the pathology of Meniere’s disease. The increased inflammatory
reaction could be caused by various etiologies such as allergy, viral
infection, genetic cause, or autoimmunity. Although direct
evidence of autoimmunity was not found in the luminal fluid
analysis, our results about the presence of circulating autoanti-
bodies and increased immune reaction between patients’ sera and
mouse inner ear tissue could support the possibility of autoimmu-
nity as a cause of increased immune/inflammatory reaction in the
inner ear. If autoimmunity was the cause of the increased
inflammatory reactions the autoantibodies responsible for these
reactions have a molecular weight between 17 and 26 kDa and
between 55 and 63 kDa as revealed by LC-MS/MS in our results.
Evidences for autoimmune reactions in the inner ear of patients
with Meniere’s disease have been reported. One report demon-
strated the presence of focal inflammation with intraepithelial
invasion by mononuclear cells in the ES of patients with Meniere’s
disease that altered the normal structures in the endolymphatic sac
[22]. The authors of this study suggested that autoimmune
reactions may have triggered the inflammatory changes in the ES.
Another report showed that an antigen-antibody reaction
between sera from patients with Meniere’s disease and human
endolymphatic sac tissue was detected by immunohistochemistry
in 10% of patients [23]. However, no study has comprehensively
analyzed the protein components of the inner ear fluid of patients
with Meniere’s disease. This is the first study to investigate the
difference in protein constituents of the ES luminal fluid of
controls and patients with Meniere’s disease and to provide
supportive evidence for the involvement of autoimmunity in the
pathogenesis of Meniere’s disease.
However, there were limitations in our study associated with the
use of LC-MS/MS to analyze the ES luminal fluid. First, we could
Figure 4. Difference in signal intensity of controls and patients in the Protoarray experiment. A. Raw signals of Protoarray chips of
control and Meniere’s disease patient. B. Normalized signal intensities of the antigens with a signal intensity more than 10-fold higher in the patients
with Meniere’s disease than in the controls. IGHG1, immunoglobulin heavy constant gamma 1; RGS10, regulator of G-protein signaling 10, transcript
variant 2; C2orf34, chromosome 2 open reading frame 34; SH3GLB1, SH3-domain GRB2-like endophilin B1; ACY1, aminoacylase 1; CAMK4, calcium/
calmodulin-dependent protein kinase IV; GSG1L, GSG1-like (GSG1L), transcript variant 2, mRNA. Red bars and error bars represent the mean
normalized signal intensity and the SE, respectively.
doi:10.1371/journal.pone.0111039.g004
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not compare the amounts of certain proteins or peptides, as this
technique could only identify the types of proteins contained in the
fluid. A comparative analysis with the iTRAQ technique could
have quantified the amounts of protein in the controls and
patients. However, the amount of ES luminal fluid sampled from
each person was too small (less than 200 ml after dilution) to be
quantified by iTRAQ and exact quantification after dilution is
impossible. In addition, the development of less-invasive therapies
such as the use of intratympanic steroids or gentamicin injections
has limited the need for ES surgery and therefore the opportunities
to sample ES luminal fluid. Additionally, although many
immunoglobulins and their variants were detected in the LC-
MS/MS analysis, it remains unclear whether these proteins acted
as autoantibodies. Immunoprecipitation using human inner ear
fluid and the inner ear or using human inner ear fluid and animal
inner ear samples would need to be performed, and the identity of
the autoantibody would need to be confirmed with mass
spectrometry. However, these experiments would be difficult to
perform for ethical reasons and because of the limited amounts of
human inner ear fluid. Microanalysis techniques with very small
amounts of sample should be performed to confirm the occurrence
of autoimmunity in the future.
Evidence of circulating autoantibodies in patient sera
We sought to determine whether circulating autoantibodies
were present in the sera of the patients, as inner ear fluid is difficult
to sample for practical use; this limitation precludes the study of
the pathologic mechanisms underlying Meniere’s disease in large
numbers of patients. Detectable autoantibodies or evidence of
autoimmunity in the serum could be used as diagnostic biomarkers
in conjunction with mass screening. There were several reports
investigating the difference of serum protein profiles between
Meniere’s disease patients and controls using proteomics as a
screening method. Proteins related to immune reaction or inner
ear disorder such as complement factor H, b2 glycoprotein 1,
vitamin D binding protein, and b actin were previously reported to
be increased in the serum of Meniere’s disease by proteomic
analysis [15]. Additionally, fibrinogen a and c chains, b2
glycoprotein, and complement factor B and H were revealed to
be differently expressed according to hearing threshold of patients
[24]. However, this study eliminate serum abundant proteins such
as albumin and immunoglobulins for 2-DE analysis and
performed LC-MS/MS in the several spots that were different
between Meniere’s disease and control after image analysis.
Therefore, most circulating antibodies could be excluded in the
analysis and only targeted spots were analyzed by LC-MS/MS;
the study did not focused on the Ag-Ab reaction between
circulating antibodies and corresponding antigens, but analyzed
proteins exclusively increased in the serum of Meniere’s disease
patients. In our study, we tried to investigate Ag-Ab reaction
between circulating antibodies and target antigens using Proto-
array and consequently detected circulating antibodies to 18
candidate proteins which could be involved in autoimmune
reactions in the patients; the signal intensity of these proteins was
more than 2-fold higher in the patients with Meniere’s disease
than in the controls. With the exception of IGHG1, all of these
proteins were located in the membrane or subcellular areas
(information on the localization of these proteins can be found at
Figure 5. Western blot of the reaction of serum from controls and patients with mouse inner ear. Red, blue, and yellow arrows represent
the detected inner ear antigens with molecular weights of 63–75 kDa, 35–48 kDa, and 25–25 kDa, respectively. C, control; P, patient. Co, mouse
cochlear tissue protein, V, mouse vestibular tissue protein.
doi:10.1371/journal.pone.0111039.g005
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http://www.uniprot.org). These proteins are known to be
involved in cell signaling, mitochondrial structure, receptor gating,
cell mitotic activity, ganglioside biosynthesis, fasciculation, neuro-
peptides, DNA splicing and repair, cytokinesis, and maintaining
neurotransmitter release sites (Table 3). However, the functions of
some of these proteins, including cDNA clone IMAGE:4155919,
complete cds, and Mitochondrial coiled-coil domain protein 1
(MCCD1), are unknown. Among those proteins, only mRNA of
CAMK4, NEK 7, and PCLO were reported to exist in the inner
ear sensory epithelium and ribbon synapse [25], but the existence
of the other proteins in the human inner ear has not been
demonstrated. PCLO is thought to be involved in the synaptic
neurotransmission in the inner ear, although its functional
relevance is still unclear [26]. If autoantibodies for PCLO in
Meniere’s disease deteriorate the inner ear function by reacting
with PCLO in the ribbon synapse, it could be one of the candidate
autoantibodies for the disease. However, a truncated splice variant
of PCLO, piccolino, which could maintain the integrity of synaptic
transmission in the absence of PCLO in the retina ribbon synapse,
was also found in the sensory ribbon synapse of the cochlea [27].
Therefore, the synaptic transmission can remain intact, even with
the Ag-Ab reaction between autoantibodies and PCLO in the
inner ear. The function of the other proteins which were reported
to exist in the inner ear still remains unknown.
The enhanced immune reaction associated with IGHG1 could
be explained in several ways. First, an immune complex
autoimmune disorder could explain this occurrence. Circulating
autoantibodies to immunoglobulins could form immune complex-
es that may cause inner ear damage via a type III hypersensitivity
reaction. Indeed, several studies have reported elevated circulating
immune complexes in 54–94% of patients with Meniere’s disease
[28,29]. However, other studies have shown evidence of circulat-
ing immune complexes in only 4–7.4% of patients [30,31]. Several
methods can be used to detect circulating immune complexes;
however, none of these methods can detect all types of circulating
immune complexes. Therefore, the prevalence of patients with
circulating immune complexes may vary from study to study.
Differences in the race and number of patients enrolled in a study
can also influence the prevalence of circulating immune complex-
es. Evidence of damage to the inner ear associated with circulating
immune complexes is important in the pathogenesis of Meniere’s
disease. However, evidence for inner ear pathology is insufficient,
even though histopathological studies of the human temporal bone
have demonstrated that patients with Meniere’s disease have C3
and C1q deposits in their inner ear [32,33].
Second, increased amounts of anti-IGHG1 antibodies in
patients with Meniere’s disease may be a result of an excessive
autoimmune or inflammatory reaction in the inner ear. It is also
possible that increased concentrations of anti-IGHG1 antibody are
involved in regulating the immune system and suppressing
excessive immune reactions by reducing B cell activity. Other
antibodies may cause autoimmune reactions at a cellular level and
affect the function of the epithelial cells of the inner ear that
regulate inner ear homeostasis via the disruption of cell signaling
or cellular structures. Such autoimmune reactions could result in
secondary increases in the concentrations of anti-immunoglobulin
antibodies.
Evidence of an immune reaction between patient serum
and the inner ear
Demonstrating the presence of immune reaction between
circulating autoantibodies in the serum and the inner ear tissue
is important. We used western blots with proteins from mouse
inner ear tissue and patient serum to demonstrate the existence of
this type of immune reaction. The western blots showed that more
antigen-antibody reactions occurred in the patients with Meniere’s
disease than in the controls. Animal inner ear antigens that have
been reported to react with sera from patients with Meniere’s
disease have molecular weights in the 32–35 kDa, 42–46 kDa, 52–
59 kDa, and 79–80 kDa ranges [18]. Microsequencing showed
that the 28 KDa and 42 KDa antigens corresponded to Raf-1 and
beta actin, respectively [18]. These antigens have been detected in
a variety of species, including guinea pigs, cows, and humans,
suggesting that the antigens might be organ-specific rather than
species-specific. In our experiment, inner ear antigens with
molecular weights in the 25–35 kDa, 35–48 kDa, and 57–
63 kDa ranges were detected. These antigens are likely to be
similar to those detected in previous studies. Although the identity
of these antigens can be conjectured from the antigens with similar
molecular weight detected in the Protoarray experiment as
suggested in the result, it should be further studied using
immunoprecipitation of patient serum and inner ear tissues
followed by mass spectrometry of the corresponding protein
bands.
We divided the mouse inner ear tissue into cochlear and
vestibular tissues and investigated whether an antigen-antibody
reaction between these tissues and patient serum occurred. In
contrast, previous studies tended to use whole inner ear tissue. We
found that each antigen reacted with the serum differently;
samples of patient serum could react with the cochlear tissue, with
the vestibular tissue, or with both. Clinically, cochlear and
vestibular symptoms in Meniere’s disease are different for each
patient. In general, vestibular symptoms tend to coincide with
cochlear symptoms. However, the progression of each cochlear
and vestibular symptom and function varies from patient to
patient. The varying antigen-antibody reactions observed in each
tissue may be associated with the varying clinical features of the
disease.
Because a variety of inner ear antigens could react with patient
serum, it appears that multiple target antigens and autoantibodies
(rather than a single antigen-antibody combination) may be
responsible for the autoimmune reaction associated with Meniere’s
disease. The 1-DE findings examining the protein composition of
the ES luminal fluid of patients with Meniere’s disease also support
this hypothesis: the distribution of bands was different in the 3
patients, suggesting that the protein composition of the ES luminal
fluid of each patient was different and that different antibodies or
inflammatory materials are present in each patient.
Clinical and future implications
The diagnosis of Meniere’s disease is based on clinical
symptoms of vertigo and fluctuations in hearing; the diagnosis is
confirmed by showing evidence of sensorineural hearing loss using
the pure tone audiogram, as recommended by the AAO-HNS
[1995] [16]. Other clinical tests, including vestibular function tests,
electrocochleography, and the glycerol test, are not as useful for
diagnosing Meniere’s disease. Because the diagnostic criteria are
primarily symptom-based, differentiating Meniere’s disease from
other vestibular disorders such as vestibular migraine, vestibular
paroxysmia, and sudden sensorineural hearing loss with vertigo
can be difficult. Diagnostic markers that can more accurately
diagnose Meniere’s disease are therefore needed. Biologic markers
can potentially decrease the cost of diagnosing Meniere’s disease
by avoiding unnecessary laboratory and imaging work-ups and
promoting proper treatment after accurate diagnosis. If autoim-
munity is one of the causes of Meniere’s disease, detecting
autoantibodies or inflammatory materials can be useful.
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Highly sensitive experimental chips using candidate antigens
(such as the 18 antigens detected in our study) can be
manufactured to avoid the need to use the expensive conventional
screening chips used in our study. These diagnostic chips should
contain multiple candidate antigens, as multiple candidate
antigens were detected in our study and in previous reports. A
prospective study using experimental chips should be undertaken
in a large population, and highly sensitive and specific markers
should be chosen. This type of study will enable subtypes and the
prognosis of patients with Meniere’s disease to be classified.
Understanding the pathophysiology underlying Meniere’s disease
can also contribute to the development of new treatment methods.
None of the current treatments for Meniere’s disease can prevent
the progression of the disease. Prospective, randomized controlled
studies using anti-inflammatory agents such as TNF-a or steroids
would be performed in a large population in the patients with
autoimmune pathology if it can be confirmed by the autoimmu-
nity screening.
Many studies have attempted to describe the pathophysiology of
Meniere’s disease; however, our understanding of the pathophys-
iology of this disease remains limited. In fact, Meniere’s disease is a
syndrome which may be caused by multiple factors. Autoimmu-
nity is one of the candidate etiologies and thought to represent less
than 20%. Recently, familial aggregation for Meniere’s disease
was reported to be as high as 10–20% [6,8]. This represents a
significant role for genetics in Meniere’s disease. Among the
various candidate genes associated with Meniere’s disease, several
genes related to immune response were reported to determine an
increased susceptibility of Meniere’s disease. Genes that were
revealed to be associated with bilateral Meniere’s disease, chronic
balance/hearing loss were allelic variants of DRB1, PTPN22,
TLR 10, MICA genes [34–36]. Genetic factors can be one of the
causes of autoimmunity or increased immune reaction in
Meniere’s disease. If various candidate genes associated with
Meniere’s disease are revealed in the future, it can also be used as
evidence for developing new treatment method as well as
diagnostic and prognostic markers. However, so far, at least 60–
70% of etiologies of Meniere’s disease remains unknown, and
considerable efforts should be taken to investigate the etiopatho-
genesis of Meniere’s disease using new molecular technologies.
Conclusion
The findings of this study suggest that autoimmunity could be
one of the pathologic mechanisms behind Meniere’s disease.
Multiple autoantibodies and antigens may be involved in the
autoimmune reaction. Specific antigens that caused immune
reactions with patient’s serum in Protoarray analysis can be
candidates for the diagnostic biomarkers of Meniere’s disease.
Further studies with mass screening using candidate antigen-
antibody reactions are needed to identify future treatment
modalities and to determine the true prevalence of autoimmune
pathologic mechanisms underlying Meniere’s disease.
Supporting Information
Table S1 LC-MS/MS profiles of the 8 proteins that were found
only in the 3 patients with Meniere’s disease. Each sheet of Excel
data presents the protein profile of each patient.
(XLS)
Table S2 Signal intensities of antigen-antibody reactions and
peptide sequences of the 18 antigens with a Protoarray signal
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